Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 301–400 of 1,640
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
Dysfunction of Microglial STAT3 Alleviates Depressive Behavior via Neuron–Microglia Interactions
Kwon, S.-H., Han, J.-K., Choi, M., Kwon, Y.-J., Kim, S. J., Yi, E. H., Shin, J.-C., Cho, I.-H., Kim, B.-H., Jeong Kim, S., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.93 · Cited by 66
“As neuronal mechanisms of depression, the increased synaptic transmission could be a potent mechanism from a therapeutic point of view (Duman and Aghajanian, 2012a).”
BackgroundShweiki, M. R. A., Oeckl, P., Steinacker, P., Barschke, P., Dorner‐Ciossek, C., Hengerer, B., Schönfeldt‐Lecuona, C., & Otto, M. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0825-7 · Cited by 66
Lv, Q., Yang, L., Li, G., Wang, Z., Shen, Z., Yu, W., Jiang, Q., Hou, B., Pu, J., Hu, H., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.028 · Cited by 75
“There is increasing recognition that therapeutic interventions could generate structural and functional network reorganization through the possible neural plasticity (4,7) and regulate system-level abnormalities in the brain, eventually leading to complete rehabilitation.”
InfluentialBenedetti, F., Poletti, S., Locatelli, C., Mazza, E., Lorenzi, C., Vitali, A., Riberto, M., Brioschi, S., Vai, B., Bollettini, I., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.011 · Cited by 64
“Factors affecting neuronal plasticity and glutamatergic neurotransmission could play a role in pathophysiology and treatment response in BD (Duman and Aghajanian, 2012; Lener et al., 2016), and could provide new treatment targets and translational models (Zarate et al.”
Mechanisms underlying the neuroprotective effect of brain reserve against late life depression
Fréret, T., Gaudreau, P., Schumann‐Bard, P., Billard, J., & Popa‐Wagner, A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1154-2 · Cited by 72
“Basic and clinical studies have shown that depression is associated with decreased densities in neuronal synapses in the prefrontal cortex and hippocampus, two brain regions that regulate mood and cognition (Duman and Aghajanian 2012).”
BackgroundChang, J., Jiang, T., Shan, X., Zhang, M., Li, Y. Y., Qi, X., Bian, Y., & Zhao, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110931 · Cited by 79
Wei, J., Zhong, P., Qin, L., Tan, T., & Yan, Z. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhx104 · Cited by 65
Effects of ketamine on cognition–emotion interaction in the brain
Scheidegger, M., Henning, A., Walter, M., Boeker, H., Weigand, A., Seifritz, E., & Grimm, S. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.08.070 · Cited by 64
“…the notion that NMDA-receptor antagonism is not only relevant to cognitive, but also to emotional processing is supported by the rapid antidepressant effect of ketamine in otherwise treatment-resistant MDD patients (Aan Het Rot et al., 2012; Duman and Aghajanian, 2012; Zarate et al., 2006).”
The Neurobiology of Motivational Deficits in Depression—An Update on Candidate Pathomechanisms
Treadway, M. T. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_400 · Cited by 73
NMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 71
“Synaptic plasticity may play a major role in the potential factors the antidepressant effects of ketamine along with the recovery from the depressive episode [31].”
Zhang, J.-C., Yao, W., Ren, Q., Yang, C., Dong, C., Ma, M., Wu, J., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep36705 · Cited by 86
Effects of chronic mild stress induced depression on synaptic plasticity in mouse hippocampus
Hei, M., Chen, P., Wang, S., Li, X., Xu, M., Zhu, X., Wang, Y., Duan, J., Huang, Y., & Zhao, S. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.044 · Cited by 63
“Increasing evidence proves that depression is associated with abnormal synaptic development [7], in particular, disrupting the homeostatic mechanisms of synaptic plasticity can lead to the atrophy of neurons and reduce connectivity in clinical and preclinical studies [8].”
Nitric oxide signalling and antidepressant action revisited
Joca, S. R. L., Sartim, A. G., Roncalho, A. L., Diniz, C. F. A., & Wegener, G. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02987-4 · Cited by 63
He, J., Zhou, H.-Y., Xue, S.-G., Lu, J.-J., Xu, J.-F., Zhou, B., Hu, Z., Wu, P., Long, L., Ni, L., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.09.003 · Cited by 71
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“…share many common features with AD and related dementias including cortical atrophy, synapse loss, and inflammation (Autry & Monteggia, 2012; Christoffel et al., 2011; Duman & Aghajanian, 2012; Duman et al., 2016; Izquierdo et al., 2006; Qiao et al., 2016; Raison, 2016; Russo et al., 2009, 2013).”
BackgroundBioinspired nanofluidic iontronics for brain-like computing
Yu, L., Li, X., Luo, C., Lei, Z., Wang, Y., Hou, Y., Wang, M., & Hou, X. (2023) · Nano Research · doi:10.1007/s12274-023-5900-y · Cited by 72
What Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders
Musazzi, L., Tornese, P., Sala, N., & Popoli, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00758 · Cited by 76
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Ru, Q., Lu, Y., Saifullah, A. B., Blanco, F. A., Yao, C., Cata, J. P., Li, D., Tolias, K. F., & Li, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158545 · Cited by 71
“Whereas neuronal atrophy and synaptic loss in the PFC and hippocampus are hypothesized to cause stress-induced depression (56), our data and others suggest that spinogenesis and synaptic potentiation in the ACC promote chronic pain–induced depressive-like behav-Figure key neural substrate for the…”
Walker, A. J., Kim, Y., Price, J. B., Kale, R. P., McGillivray, J., Berk, M., & Tye, S. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00034 · Cited by 71
Zhang, J., Cai, C.-Y., Wu, H., Zhu, L., Luo, C., & Zhu, D. (2016) · Scientific Reports · doi:10.1038/srep29551 · Cited by 65
“6E) and distance in center in OF test (F(2,42) = 8.”
BackgroundZhu, X.-L., Chen, J., Han, F., Pan, C., Zhuang, T.-T., Cai, Y., & Lu, Y.-P. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4915-7 · Cited by 63
Lazarevic, V., Yang, Y., Ivanova, D., Fejtová, A., & Svenningsson, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.021 · Cited by 64
“Indeed, the hypothesis that mood/anxiety disorders are accompanied by a reduced availability of monoamines has been expanded to the “neuroplasticity hypothesis” that also involves the role of glutamate and excitatory transmission in mediating the complex emotional and cognitive changes associated with depression (Duma…”
Pignatelli, M., Tejeda, H. A., Barker, D. J., Bontempi, L., Wu, J., Lopez, A., Ribeiro, S. P., Lucantonio, F., Parise, E. M., Torres‐Berrío, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0686-8 · Cited by 63
The Netrin-1/DCC Guidance Cue Pathway as a Molecular Target in Depression: Translational Evidence
Torres-Berrío, A., Hernandez, G., Nestler, E. J., & Flores, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.04.025 · Cited by 61
“These structural alterations comprise impaired signaling of proteins that are essential for neuronal morphology and synaptic plasticity, resulting in cortical dysfunction (13,15,17).”
BackgroundThe Timing Effect of Childhood Maltreatment in Depression: A Systematic Review and meta-Analysis
Li, M., Gao, T., Su, Y., Zhang, Y., Yang, G., D’Arcy, C., & Meng, X. (2022) · Trauma Violence & Abuse · doi:10.1177/15248380221102558 · Cited by 67
Machado, N. J., Simões, A. P., Silva, H. B., Ardais, A. P., Kaster, M. P., Garção, P., Rodrigues, D. I., Pochmann, D., Santos, A. I., Araújo, I. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9774-9 · Cited by 61
“One lead is synaptic dysfunction, since in most conditions where memory performance is affected [8–10], depressed individuals and chronically stressed animals display dendritic atrophy, changes in spine density, and loss of synapses and synaptic markers [11].”
BackgroundResultLiebe, T., Li, S., Lord, A., Colic, L., Krause, A. L., Batra, A., Kretzschmar, M. A., Sweeney-Reed, C. M., Behnisch, G., Schott, B. H., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx055 · Cited by 61
“It remains unclear whether a peripheral elevation of NE through NET inhibition or a central influence of ketamine on noradrenergic (Schroeder, 2012) or glutamatergic transmitter systems (Boyer et al., 1998; Berman et al., 2000; Duman and Aghajanian, 2012) predominantly influences the cardiovascular side effects.”
BackgroundStress-induced Changes in the S-palmitoylation and S-nitrosylation of Synaptic Proteins*[S]
Zaręba-Kozioł, M., Bartkowiak-Kaczmarek, A., Figiel, I., Krzystyniak, A., Wójtowicz, T., Bijata, M., & Włodarczyk, J. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001581 · Cited by 62
Aten, S., Du, Y., Taylor, O., Dye, C., Collins, K., Thomas, M., Kiyoshi, C., & Zhou, M. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03663-4 · Cited by 60
Subanesthetic Ketamine Reactivates Adult Cortical Plasticity to Restore Vision from Amblyopia
Grieco, S. F., Qiao, X., Zheng, X., Liu, Y., Chen, L., Zhang, H., Yu, Z., Gavornik, J. P., Lai, C., Gandhi, S. P., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.07.008 · Cited by 60
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview
Bortolozzi, A. A., Fico, G., Berk, M., Solmi, M., Fornaro, M., Quevedo, J., Zarate, C. A., Kessing, L. V., Vieta, E., & Carvalho, A. F. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000007 · Cited by 73
New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine
Grizzell, J. A., & Echeverría, V. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1359-2 · Cited by 67
“synaptic plasticity and neurogenesis, particularly in the PFC and hippocampus [122], therefore, cotinine-induced”
Henderson, T. A., & Morries, L. D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00187 · Cited by 60
Kohtala, S., Theilmann, W., Rosenholm, M., Penna, L., Karabulut, G., Uusitalo, S., Järventausta, K., Yli-Hankala, A., Yalcin, I., Matsui, N., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1364-6 · Cited by 60
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
“Ultimately, these events activate the mTOR signaling pathway, affecting downstream changes in dendritic spines and local synaptic protein synthesis, including BDNF (Duman and Aghajanian 2012).”
InfluentialMa, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep39209 · Cited by 59
The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications
Gold, P. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179248 · Cited by 60
Wang, H., Zhang, R., Qiao, Y., Xue, F., Nie, H., Zhang, Z., Wang, Y., Peng, Z., & Tan, Q. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.046 · Cited by 59
Liu, R.-J., Ota, K. T., Dutheil, S., Duman, R. S., & Aghajanian, G. K. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.70 · Cited by 62
“These studies extend previous work demonstrating mTORC1-dependent synaptogenic effects on input to apical dendrites (see the study by Duman and Aghajanian (2012)).”
BackgroundResultInfluentialSelf-citationLiu, S., Li, D., Zeng, H.-Y., Kan, L.-Y., Zou, W., Zhang, P., Gu, H., & Tang, X. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx030 · Cited by 58
“It is widely accepted that dysfunction of synaptic plasticity contributes to the pathophysiology of depression (Duman, 2002; Duman and Aghajanian, 2012).”
BackgroundMcGirr, A., LeDue, J., Chan, A. W., Xie, Y., & Murphy, T. H. (2017) · Brain · doi:10.1093/brain/awx142 · Cited by 59
Harrill, J., Chen, H., Streifel, K. M., Yang, D., Mundy, W. R., & Lein, P. J. (2015) · Molecular Brain · doi:10.1186/s13041-015-0099-9 · Cited by 72
“Synaptic connections increase in parallel to dendritic development, and abnormalities in dendritic length are associated with changes in synapse number and function [24-29].”
BackgroundBanov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 66
The aging brain: sleep, the circadian clock and exercise
Panagiotou, M., Michel, S. H., Meijer, J. H., & Deboer, T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114563 · Cited by 72
Shen, S.-Y., Yu, R., Li, W., Liang, L., Han, Q.-Q., Huang, H., Li, B., Xu, S., Wu, G.-C., Zhang, Y., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105743 · Cited by 67
“cated in the development of psychiatric and neurological pathologies, such as depression(Anacker and Hen, 2017; Duman and Aghajanian, 2012; Toda et al., 2019).”
BackgroundFerrés-Coy, A., Galofré, M., Pilar-Cuéllar, F., Vidal, R., Paz, V, Ruiz-Bronchal, E., Campa, L., Pazos, Á., Caso, J. R., Leza, J. C., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.80 · Cited by 57
Macaques Exhibit a Naturally-Occurring Depression Similar to Humans
Xu, F., Wu, Q., Xie, L., Gong, W., Zhang, J., Zheng, P., Zhou, Q., Ji, Y., Wang, T., Li, X., et al. (2015) · Scientific Reports · doi:10.1038/srep09220 · Cited by 59
Emerging Roles of BAI Adhesion-GPCRs in Synapse Development and Plasticity
Duman, J. G., Tu, Y.-K., & Tolias, K. F. (2016) · Neural Plasticity · doi:10.1155/2016/8301737 · Cited by 60
“Furthermore, since stress and depression are known to induce synapse loss, while antidepressants promote synaptogenesis [52], in future studies it will be interesting to investigate the possible roles of BAI2 at synapses.”
BackgroundForkhead box O transcription factors as possible mediators in the development of major depression
Wang, H., Quirion, R., Little, P. J., Cheng, Y., Feng, Z., Sun, H., Xu, J., & Zheng, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.020 · Cited by 61
“…and preclinical studies have revealed that prolonged stress and major depression are associated with decreased neuronal synapses, neuronal atrophy of the PFC and the hippocampus M AN US CR IP T AC CE PT ED (Duman and Aghajanian, 2012; Ota et al., 2014; Sheline et al., 2003; Sheline et al., 1996).”
Oliveira-Maia, A. J., Press, D. Z., & Pascual‐Leone, Á. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.03.013 · Cited by 64
“Furthermore, antidepressant treatments such as rTMS, as well as ketamine, an experimental rapid-acting drug [5,21], are thought to act through the modulation of synaptic function [49].”
Nadjar, A., Wigren, H., & Tremblay, M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00250 · Cited by 63
“Synaptic loss is considered the best pathological correlate of cognitive decline across a variety of conditions that include aging and neurodegenerative diseases (Duman and Aghajanian, 2012; Spires-Jones and Hyman, 2014).”
BackgroundHan, Y.-X., Tao, C., Gao, X.-R., Wang, L.-L., Jiang, F.-H., Wang, C., Fang, K., Chen, X.-X., Chen, Z., & Ge, J.-F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00731 · Cited by 57
“, 2017), and increasing evidence has demonstrated the relationship between synaptic dysfunction and depression (Duman and Aghajanian, 2012).”
BackgroundCui, Q., Hu, Z., Hu, Y., Chen, X., Wang, J., Mao, L., Lu, X., Ni, M., Chen, J., & Wang, F. (2020) · The EMBO Reports · doi:10.15252/embr.201947857 · Cited by 56
“It has been reported that depression is associated with alterations in dendritic and synaptic structure and function [29,30], and chronic stress leads to the reduction of dendritic complexity and spine density in DG, CA1, and CA3 [31,32].”
BackgroundXu, A., Cui, S., & Wang, J.-H. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv122 · Cited by 56
“The structures and functions of GABAergic and glutamatergic units in prelimbic cortices were studied by cell imaging and electrophysiology in chronic unpredictable mild stress-induced depression mice vs controls.”
InfluentialPropofol Induces Postoperative Depression and Inhibits Microglial Function in Mice
Song, F., Lv, X., & Meng, J. (2019) · Mediators of Inflammation · doi:10.1155/2019/7651383 · Cited by 58
“We also looked into the effect of propofol on the synaptic proteins that are very important fundamental factors behind the behavioural performances of animals [15].”
BackgroundSex Differences in Depression and Anxiety
Pavlidi, P., Kokras, N., & Dalla, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_375 · Cited by 63
Kiselycznyk, C., Jury, N. J., Halladay, L. R., Nakazawa, K., Mishina, M., Sprengel, R., Grant, S. G. N., Svenningsson, P., & Holmes, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.023 · Cited by 56
“On the other hand, increases in synaptic PSD-95 might be expected to support antidepressant-like efficacy of NMDAR antagonism by promoting dendritic spine formation and plasticity in critical circuits within the mPFC [28].”
BackgroundOn the research of time past: the hunt for the substrate of memory
Queenan, B. N., Ryan, T. J., Gazzaniga, M. S., & Gallistel, C. R. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13348 · Cited by 60
Kolp, E., Friedman, H. L., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., Hospital, A., Sylvester, M., Young, M. S., University of South Florida, et al. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.84 · Cited by 54
Zhang, J., Qu, Y., Chang, L., Pu, Y., & Hashimoto, K. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz048 · Cited by 55
“expression of these proteins in these regions, since ketamine and (R)-ketamine ameliorated these proteins (Duman and Aghajanian, 2012; Duman and Duman, 2015; Yang et al, 2015; Dong et al, 2017).”
BackgroundResultLv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Enhancing ketamine translational pharmacology via receptor occupancy normalization
Shaffer, C. L., Osgood, S. M., Smith, D. L., Liu, J., & Trapa, P. E. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.008 · Cited by 57
“The timeliness for such a critical analysis is made more urgent by the burgeoning interest (Duman and Aghajanian, 2012; Katalinic et al., 2013; Salvadore and Singh, 2013) in the rapid and sustained antidepressant effects of ketamine in select patient populations (Berman et al.”
BackgroundPålsson, E., Jakobsson, J., Södersten, K., Fujita, Y., Sellgren, C. M., Ekman, C. J., Ågren, H., Hashimoto, K., & Landén, M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.001 · Cited by 60
“, 2000) as well as in animal models of depression (Duman and Aghajanian, 2012).”
BackgroundBath, K. G., Russo, S. J., Pleil, K. E., Wohleb, E. S., Duman, R. S., & Radley, J. J. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2017.05.001 · Cited by 63
“In preclinical models of MDD these neuroplasticity deficits can be provoked by psychosocial and environmental stressors, which include repeated exposure to social defeat, restraint, or chronic unpredictable stress (Christoffel et al., 2011b; Duman and Aghajanian, 2012; Duman et al., 2016).”
Self-citationHendrikse, J. J., Kandola, A. A., Coxon, J. P., Rogasch, N. C., & Yücel, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.023 · Cited by 57
Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects
Li, M., Woelfer, M., Čolić, L., Safron, A., Chang, C., Heinze, H., Speck, O., Mayberg, H. S., Biswal, B. B., Salvadore, G., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0942-y · Cited by 60
Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
Shinohara, R., Aghajanian, G. K., & Abdallah, C. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.006 · Cited by 54
Self-citationFrase, L., Mertens, L., Krahl, A., Bhatia, K., Feige, B., Heinrich, S. P., Vestring, S., Nissen, C., Domschke, K., Bach, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01134-4 · Cited by 63
Arnsten, A. F. T., Joyce, M. K. P., & Roberts, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.105000 · Cited by 66
“Importantly, research in rodent models has shown that all of these anti-depressant medications have the shared property of restoring dendritic spines in the mPFC following chronic stress exposure (Duman and Aghajanian, 2012; Hare et al., 2017).”
BackgroundInfluentialWorkman, E. R., Haddick, P. C. G., Bush, K., Dilly, G. A., Niere, F., Zemelman, B. V., & Raab-Graham, K. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.165 · Cited by 54
Castañeda, P., Muñoz, M., García‐Rojo, G., Ulloa, J. L., Bravo, J. A., Márquez, R., García‐Pérez, M. A., Arancibia, D., Araneda, K., Rojas, P. S., et al. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23602 · Cited by 54
Meylan, E. M., Breuillaud, L., Seredenina, T. S., Magistretti, P. J., Halfon, O., Luthi‐Carter, R., & Cardinaux, J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.116 · Cited by 62
Xu, L.-Z., Xu, D.-F., Han, Y., Liu, L.-J., Sun, C.-Y., Deng, J.-H., Zhang, R.-X., Yuan, M., Zhang, S.-Z., Li, Z.-M., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw088 · Cited by 54
“…synaptic plasticity, and neurogenesis (Li and Jope, 2010; Garza et al., 2012), which in turn exerts antidepressant effects (Beurel et al., 2011; Duman and Aghajanian, 2012; Zhu et al., 2013). β-Catenin has also been implicated in neuropsychiatric disorders, including depression (Madsen…”
BackgroundResultInfluentialDysfunction of the SNARE complex in neurological and psychiatric disorders
Chen, F., Chen, H., Chen, Y., Wei, W., Sun, Y., Zhang, L., Cui, L., & Wang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105469 · Cited by 58
Zhu, X., Jing, L., Chen, C., Shao, M., Fan, Q., Diao, J., Liu, Y., Lv, Z., & Sun, X. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.11.031 · Cited by 53
Han, Y., Heuermann, R. J., Lyman, K. A., Fisher, D., Ismail, Q.-A., & Chetkovich, D. M. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.99 · Cited by 53
Advances in the Preclinical Study of Some Flavonoids as Potential Antidepressant Agents
Germán-Ponciano, L. J., Rosas-Sánchez, G. U., Rivadeneyra-Domínguez, E., & Rodríguez‐Landa, J. F. (2018) · Scientifica · doi:10.1155/2018/2963565 · Cited by 61
Lu, Y. F., Sun, G., Yang, F., Guan, Z.-W., Zhang, Z., Zhao, J., Liu, Y., Chu, L., & Pei, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109054 · Cited by 60
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02285-8 · Cited by 53
“Functionally, neuroplasticity can be thought of as the ability of the brain to change and adapt to physiological or psychological stimuli to uphold homeostasis [6].”
Microglial Responses to Stress-Induced Depression: Causes and Consequences
Afridi, R., & Suk, K. (2023) · Cells · doi:10.3390/cells12111521 · Cited by 69
“Chronic psychosocial stress causes cellular and structural changes in the brain, resulting in altered neurocircuitry and depressive behavior [41,45,46].”
BackgroundMechanisms of Action of TMS in the Treatment of Depression
Downar, J. H., Siddiqi, S., Mitra, A., Williams, N., & Liston, C. M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_483 · Cited by 66
Kerrisk, M. E., Greer, C. A., & Koleske, A. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.0528-13.2013 · Cited by 52
“, 2004), depression (Cotter et al., 2001; Duman and Aghajanian, 2012), and intellectual disability (Kaufmann and Moser, 2000; Kaufmann et al.”
BackgroundHabenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression
Rivas-Grajales, A. M., Salas, R., Robinson, M. E., Qi, K., Murrough, J. W., & Mathew, S. J. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa089 · Cited by 51
“Abnormalities in glutamate signaling have been implicated in the pathophysiology of depression (Duman and Aghajanian, 2012; Murrough et al., 2017).”
BackgroundRapid-Acting Antidepressants: Mechanistic Insights and Future Directions
Gerhard, D. M., & Duman, R. S. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0139-8 · Cited by 52
Self-citationLenze, E. J., Farber, N. B., Kharasch, E., Schweiger, J., Yingling, M., Olney, J., & Newcomer, J. W. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1142607 · Cited by 50
Elucidating the Possible Role of FoxO in Depression
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03364-4 · Cited by 52
Antidepressant drug action--From rapid changes on network function to network rewiring
Rantamäki, T., & Yalcin, I. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.001 · Cited by 50
“Reduced neurotrophin support, especially deficient BDNF (brainderived neurotrophic factor) synthesis and signaling of its receptor TrkB, is linked with the atrophic alterations associated with stress and depression (Castrén et al., 2007; Duman and Aghajanian, 2012; Duman et al., 1997).”
BackgroundSiegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., & Farber, N. B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05762-6 · Cited by 50
“…in treatment with serotonergic antidepressants (Adachi et al. 2008) and electroconvulsive therapy (Nibuya et al. 1995; Dukart et al. 2014), suggesting that the neurotrophic cascade may represent a common mechanism of antidepressant action (Duman and Monteggia 2006; Duman and Aghajanian 2012).”
BackgroundD’Alessio, L., Korman, G. P., Sarudiansky, M., Guelman, L. R., Scévola, L., Pastore, A., Obregón, A., & Ej, R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00501 · Cited by 63
Wu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., Xiao, L., & Kozorovitskiy, Y. (2021) · eLife · doi:10.7554/elife.64041 · Cited by 51
“Ketamine ameliorates depressive-like behaviors in animal models of acute and prolonged stress ( Duman et al., 2016 ; Duman and Aghajanian, 2012 ; Fuchikami et al., 2015 ; Harmer et al., 2017 ; Krishnan and Nestler, 2011 ), and rescues escape actions in response to aversive stimuli after LH…”
Ma, L., Zhang, J., Fujita, Y., Qu, Y., Shan, J., Wan, X., Wang, X., Ishima, T., Kobayashi, K., Wang, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01803-6 · Cited by 57
“9% saline, as PFC contributes to the antidepressant-like actions of ketamine and its enantiomers [32, 48, 49].”
BackgroundThe dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
“, 2013) within the glutamatergic hippocampal-prefrontal cortical circuitry (Duman and Aghajanian, 2012).”
BackgroundFeeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 64
Xu, B. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.008 · Cited by 60
Sanfilippo, C., Forlenza, O. V., Zetterberg, H., & Blennow, K. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1597-3 · Cited by 50
“We also report, for the first time, CSF Ng concentrations in patients with major depressive disorder (MDD), a common differential diagnosis to AD, which also may involve synaptic dysfunction (Duman and Aghajanian 2012).”
BackgroundLack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model
Zhang, K., Fujita, Y., & Hashimoto, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22449-9 · Cited by 49
Peng, G., Yang, L., Wu, C., Zhang, L. L., Wu, C. Y., Fan, L., Shi, H. W., Hou, J., Zhang, L. M., Ma, X., et al. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104926 · Cited by 54
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.